TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status

Journal of Translational Medicine

Research

Pilar Muñiz¹  Carlos García-Girón²  Mónica Cavia-Saiz³  Marta Herreros-Villanueva³  María J Coma del Corral³ 

[1] Departamento de Bioquímica, Universidad de Burgos, Burgos, Spain;Servicio de Oncología, Hospital General Yagüe, Burgos, Spain;Unidad de Investigación, Hospital General Yagüe, Burgos, Spain;

关键词: Oxaliplatin;    Cetuximab;    Colorectal Cancer Cell Line;    Human Colorectal Carcinoma Cell Line;    TAp73 Expression;   

DOI  :  10.1186/1479-5876-8-15

 received in 2009-08-18, accepted in 2010-02-10,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundAlthough there have been many studies on the p73 gene, some of its functions still remain unclear. There is little research on the relationship between p73 gene transcription and its protein expression and the response to certain drugs such as oxaliplatin and cetuximab, which are drugs currently used in colorectal cancer.The purpose of this study was to evaluate the impact of TAp73 expression on oxaliplatin and cetuximab-based chemotherapy in colorectal cancer cell lines with different K-Ras and B-Raf mutational status.MethodsTAp73 was analyzed in three colorectal tumor cell lines HT-29, SW-480 and Caco-2. mRNA TAp73 was determined using Real time PCR; TAp73 protein by immunoblotting and cell viability was analyzed by the MTT method.ResultsWe found that mRNA and TAp73 protein were decreased in cells treated with oxaliplatin (in monotherapy or combined with cetuximab) when B-Raf is mutated. This was statistically significant and was also associated with higher cell viability after the treatment.ConclusionsHere, for the first time we report, that there is a signaling loop between B-Raf activation and p73 function.Low expression of TAp73 in colorectal cancer cell lines with mutated B-Raf may be involved in the lack of response to oxaliplatin in monotherapy or combined with cetuximab.

【 授权许可】

CC BY   
© Herreros-Villanueva et al; licensee BioMed Central Ltd. 2010